Literature DB >> 29679113

Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma.

Yimin Li1, Frank Hofheinz2, Christian Furth3, Chen Lili1, Wu Hua4, Pirus Ghadjar5, Sebastian Zschaeck6.   

Abstract

PURPOSE: 18F-FDG uptake in irradiated non-tumour-affected oesophagus (NTO) on restaging PET is a potential surrogate for the measurement of radiation-induced inflammation. Radiation-induced inflammation itself has been shown to be of high prognostic relevance in patients undergoing preoperative radiochemotherapy (RCT) for locally advanced oesophageal cancer. We assessed the prognostic relevance of FDG uptake in the NTO in an independent cohort of patients treated with definitive RCT.
METHODS: This retrospective evaluation included 72 patients with oesophageal squamous cell carcinoma treated with definitive RCT with curative intent. All patients underwent pretreatment and restaging FDG PET after receiving a radiation dose of 40-50 Gy. Standardized uptake values (SUVmax/SUVmean), metabolic tumour volume (MTV) and relative changes from pretreatment to restaging PET (∆SUVmax/∆SUVmean) were determined within the tumour and NTO. Univariate Cox regression with respect to overall survival (OS), local control (LC), distant metastases (DM) and treatment failure (TF) was performed. Independence of parameters was tested by multivariate Cox regression.
RESULTS: ∆SUVmax NTO and MTV were prognostic factors for all investigated clinical endpoints (OS, LC, DM, TF). Inclusion of clinical and PET tumour parameters in multivariate analysis showed that ∆SUVmax NTO was an independent prognostic factor. Furthermore, multivariate analysis of ∆SUVmax NTO using previously published cut-off values from preoperatively treated patients revealed that ∆SUVmax NTO was independent prognostic factor for OS (HR = 1.88, p = 0.038), TF (HR = 2.11, p = 0.048) and DM (HR = 3.02, p = 0.047).
CONCLUSION: NTO-related tracer uptake during the course of treatment in patients with oesophageal carcinoma was shown to be of high prognostic relevance. Thus, metabolically activity of NTO measured in terms of ∆SUVmax NTO is a potential candidate for future treatment individualization (i.e. organ preservation).

Entities:  

Keywords:  Definitive radiochemotherapy; FDG PET; Inflammation; Normal tissue; Oesophageal cancer; Response assessment; Restaging; Side effects

Mesh:

Substances:

Year:  2018        PMID: 29679113     DOI: 10.1007/s00259-018-3996-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  40 in total

1.  Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.

Authors:  Wing-Keen Yap; Yu-Chuan Chang; Chia-Hsun Hsieh; Yin-Kai Chao; Chien-Cheng Chen; Ming-Chieh Shih; Tsung-Min Hung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-30       Impact factor: 9.236

Review 2.  PET imaging of inflammation.

Authors:  J Buscombe
Journal:  Q J Nucl Med Mol Imaging       Date:  2014-09       Impact factor: 2.346

3.  Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.

Authors:  Steffen Löck; Rosalind Perrin; Annekatrin Seidlitz; Anna Bandurska-Luque; Sebastian Zschaeck; Klaus Zöphel; Mechthild Krause; Jörg Steinbach; Jörg Kotzerke; Daniel Zips; Esther G C Troost; Michael Baumann
Journal:  Radiother Oncol       Date:  2017-08-23       Impact factor: 6.280

4.  PET-guided treatment algorithms in oesophageal cancer: the promise of the near future!

Authors:  Lioe-Fee de Geus-Oei; Marije Slingerland
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

5.  Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.

Authors:  Kushal B Naik; Yuan Liu; Michael Goodman; Theresa W Gillespie; Allan Pickens; Seth D Force; Conor E Steuer; Taofeek K Owonikoko; Suresh S Ramalingam; Kristin Higgins; Jonathan J Beitler; Dong M Shin; Field F Willingham; Bassel El-Rayes; Jerome C Landry; Felix G Fernandez; Nabil F Saba
Journal:  Cancer       Date:  2017-05-02       Impact factor: 6.860

6.  Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets.

Authors:  F Hofheinz; C Pötzsch; L Oehme; B Beuthien-Baumann; J Steinbach; J Kotzerke; J van den Hoff
Journal:  Nuklearmedizin       Date:  2011-10-26       Impact factor: 1.379

7.  18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients.

Authors:  Elena Elimova; Xuemei Wang; Elba Etchebehere; Hironori Shiozaki; Yusuke Shimodaira; Roopma Wadhwa; Venkatram Planjery; Nikolaos Charalampakis; Mariela A Blum; Wayne Hofstetter; Jeff H Lee; Brian R Weston; Manoop S Bhutani; Jane E Rogers; Dipen Maru; Heath D Skinner; Homer A Macapinlac; Jaffer A Ajani
Journal:  Eur J Cancer       Date:  2015-08-28       Impact factor: 9.162

8.  Increasing toxicity during neoadjuvant radiochemotherapy as positive prognostic factor for patients with esophageal carcinoma.

Authors:  S Hennies; R M Hermann; J Gaedcke; M Grade; C F Hess; H Christiansen; H A Wolff
Journal:  Dis Esophagus       Date:  2013-04-09       Impact factor: 3.429

9.  Individualized Radiation Dose Escalation Based on the Decrease in Tumor FDG Uptake and Normal Tissue Constraints Improve Survival in Patients With Esophageal Carcinoma.

Authors:  Jinbo Ma; Zhaoyang Wang; Chengde Wang; Ercheng Chen; Yaozong Dong; Yipeng Song; Wei Wang; Dong You; Wei Jiang; Rukun Zang
Journal:  Technol Cancer Res Treat       Date:  2016-06-23

10.  The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG.

Authors:  Jörg van den Hoff; Liane Oehme; Georg Schramm; Jens Maus; Alexandr Lougovski; Jan Petr; Bettina Beuthien-Baumann; Frank Hofheinz
Journal:  EJNMMI Res       Date:  2013-11-23       Impact factor: 3.138

View more
  4 in total

1.  Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma.

Authors:  Frank Hofheinz; Yimin Li; Ingo G Steffen; Qin Lin; Chen Lili; Wu Hua; Jörg van den Hoff; Sebastian Zschaeck
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-04       Impact factor: 9.236

2.  Prognostic value of fibroblast activation protein expressing tumor volume calculated from [68 Ga]Ga-FAPI PET/CT in patients with esophageal squamous cell carcinoma.

Authors:  Liang Zhao; Yizhen Pang; Shanyu Chen; Jianhao Chen; Yimin Li; Yifeng Yu; Chunbin Huang; Long Sun; Hua Wu; Haojun Chen; Qin Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-10-12       Impact factor: 10.057

3.  The noncoding function of NELFA mRNA promotes the development of oesophageal squamous cell carcinoma by regulating the Rad17-RFC2-5 complex.

Authors:  Jiancheng Xu; Guangchao Wang; Wei Gong; Shichao Guo; Dan Li; Qimin Zhan
Journal:  Mol Oncol       Date:  2020-01-28       Impact factor: 6.603

4.  A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation.

Authors:  Yimin Li; Marcus Beck; Tom Päßler; Chen Lili; Wu Hua; Ha Dong Mai; Holger Amthauer; Matthias Biebl; Peter C Thuss-Patience; Jasmin Berger; Carmen Stromberger; Ingeborg Tinhofer; Jochen Kruppa; Volker Budach; Frank Hofheinz; Qin Lin; Sebastian Zschaeck
Journal:  Sci Rep       Date:  2020-10-19       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.